Recurrent Adult Primary Liver Cancer Clinical Trial
Official title:
A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation
PRIMARY OBJECTIVES: I. Two-year recurrence free survival (RFS). SECONDARY OBJECTIVES: I. One-year recurrence free survival. II. Overall survival (OS). III. Safety. IV. Impact of drug-drug interactions (i.e. immunosuppression agents). V. Impact of biomarkers (alpha-fetoprotein [AFP], protein-induced by vitamin K absence or antagonist II [PIVKA II]). VI. Effects of therapy on wound healing. VII. Impact of hepatitis C viral recurrence. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive sorafenib tosylate orally (PO) twice daily (BID). ARM II: Patients receive placebo PO BID. In both arms treatment continues for 24 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00787787 -
Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00052364 -
Oxaliplatin in Treating Patients With Liver Cancer
|
Phase 2 | |
| Completed |
NCT01229111 -
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
|
Phase 2 | |
| Completed |
NCT00107536 -
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT02072356 -
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
|
Early Phase 1 | |
| Completed |
NCT00604721 -
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00101036 -
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
| Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT01766219 -
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00427973 -
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
|
Phase 2 | |
| Completed |
NCT00321594 -
Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT00639509 -
IMC-A12 in Treating Patients With Advanced Liver Cancer
|
Phase 2 | |
| Completed |
NCT00083226 -
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
|
Phase 2 | |
| Completed |
NCT00033462 -
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02119065 -
Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT
|
||
| Withdrawn |
NCT01859182 -
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
| Completed |
NCT00844168 -
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
|
Phase 1 | |
| Completed |
NCT00397384 -
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT00085410 -
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
|
Phase 2 |